Đang chuẩn bị liên kết để tải về tài liệu:
Chapter 086. Breast Cancer (Part 8)

Table 86-3 Suggested Approaches to Adjuvant Therapy Age Group h Lymp Endocr Tum tion Recommenda Node ine Receptor or (ER) Status Statusa Premenopa usal ve Positi Any Any Multidrug chemotherapy tamoxifen positive if + ER+ trastuzumab in HER- 2/neu tumors positive Premenopa usal ive Negat Any 2 Multidrug + ER+ cm, or 1–2 chemotherapy cm with tamoxifen if other poor positive prognostic trastuzumab in HERvariables 2/neu tumors positive Postmenopa usal ve Positi e Negativ Any Multidrug chemotherapy + trastuzumab in HER2/neu tumors positive Postmenopa usal ve Positi Positive Any Aromatase inhibitors and tamoxifen with or without chemotherapy + trastuzumab in HER2/neu tumors positive Postmenopa usal ive Negat Positive 2 Aromatase and + cm, or 1–2 inhibitors cm with tamoxifen other poor trastuzumab in HERprognostic 2/neu variables tumors positive Postmenopa usal ive Negat e Negativ 2 Consider . | Chapter 086. Breast Cancer Part 8 Table 86-3 Suggested Approaches to Adjuvant Therapy Age Group Lymp h Node Status Endocr ine Receptor ER Status Tum or Recommenda tion Premenopa usal Positi ve Any Any Multidrug chemotherapy tamoxifen if ERpositive trastuzumab in HER- 2 neu positive tumors Premenopa usai Negat ive Any 2 cm or 1-2 cm with other poor prognostic variables Multidrug chemotherapy tamoxifen if ERpositive trastuzumab in HER-2 neu positive tumors Postmenopa usai Positi ve Negativ e Any Muitidrug chemotherapy trastuzumab in HER-2 neu positive tumors Postmenopa usai Positi ve Positive Any Aromatase inhibitors and tamoxifen with or without chemotherapy trastuzumab in HER-2 neu positive tumors Postmenopa usal Negat ive Positive 2 cm or 1-2 cm with other poor prognostic variables Aromatase inhibitors and tamoxifen trastuzumab in HER- 2 neu positive tumors Postmenopa usal Negat ive Negativ e 2 cm or 1-2 cm with other poor prognostic variables Consider multidrug chemotherapy trastuzumab in HER- 2 neu positive tumors As determined by pathologic .